DHAP (chemotherapy)
Medical intervention
From Wikipedia, the free encyclopedia
DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin lymphoma.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.
| DHAP | |
|---|---|
| Specialty | Oncology |
[R]-DHAP regimen consists of:
- Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
- Dexamethasone, a glucocorticoid hormone
- High-dose Ara-C - cytarabine, an antimetabolite;
- Platinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.
Dosing regimen
| Drug | Dose | Mode | Days |
|---|---|---|---|
| Rituximab | 375 mg/m2 | IV infusion | Day 0 |
| Dexamethasone | 40 mg | PO qd | Days 1-4 |
| High-dose Ara-C - cytarabine | 2000 mg/m2 | IV infusion over 2 hrs | Day 2, every 12 hours |
| Platinol (cisplatin) | 100 mg/m2 | IV infusion over 24 hrs | Day 1 |